Theralase Technologi (TLTFF) 0.2322 $TLTFF
Theralase Releases 2013 Financials
ACCESSWIRE - Wed Apr 30, 3:31PM CDT
Toronto, ON / ACCESSWIRE / April 30, 2014 / Theralase Technologies Inc. (herein "Theralase"
(TSXV: TLT) (TLTFF: OTCBB) released its 2013 financial results today, demonstrating an increase in profitability by 24% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.
Theralase Could Light Up Cancer Therapeutics
ACCESSWIRE - Thu Apr 24, 9:27AM CDT
Whitefish, MT / April 24, 2014 / Cancer patients don't have many good treatment options. Once the disease is detected, most oncologists will surgically remove as much as possible and then use powerful radiation and chemotherapy to kill as many cells in those areas as possible. The side effects from these treatments can be terrible and patients are at a higher risk of additional complications given the weakened state of the immune system.
Theralase Anti-Cancer Technology Validated at International Conference
ACCESSWIRE - Thu Apr 24, 6:15AM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 24, 2014 / Theralase Technologies Inc. ("Theralase' (TSXV: TLT) (TLTFF: OTCBB) announced today new research on its Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, has been peer reviewed and approved for presentation at the 16th Annual Laser Optics International Conference to be held in June 2014.
Theralase Research Accepted at International Conference
ACCESSWIRE - Tue Apr 22, 6:05AM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 22, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that its Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, has been peer reviewed and approved for presentation at the renowned International Conference on Laser Applications in Life Sciences to take place in Ulm, Germany in June 2014.
Theralase Advances Sales and Marketing
ACCESSWIRE - Tue Apr 15, 6:22AM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 15, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that it is advancing on its sales and marketing mandate through the hiring of Mr. Derek Small as Director of Sales and Marketing.
Theralase Developing Next Generation Medical Lasers
ACCESSWIRE - Tue Mar 25, 6:13AM CDT
Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the expansion of its engineering team to develop and commercialize its next generation of smart medical laser technologies. This highly trained engineering team will be instrumental in developing Theralase products to eliminate pain and heal tissue, a $100 Billion industry in the US and to destroy cancer, a $77 Billion industry in the US.
Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Mar 12, 6:05AM CDT
Theralase Technologies Inc. (OTCBB: TLTFF) (TSX VENTURE: TLT) sells patented, superpulsed laser technology to healthcare practitioners to heal damaged tissue and eliminate pain. Theralase is also developing the next generation cancer treatment combining patented light activated compounds with laser technology to hunt down and destroy cancer.
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra...
ACCESSWIRE - Thu Feb 13, 6:01AM CST
Toronto, Ontario - February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25).
Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
ACCESSWIRE - Wed Feb 12, 9:20AM CST
2013 was a great year for Life Sciences stocks and the momentum created last year is being carried into 2014 - with a flurry of successful IPOs and financings. According to organizers at the JP Morgan Health Care Conference in January attendance was much higher than what they had anticipated and bankers were eager to do deals as more dollars flow into the space. As the wider market draws its attention to the sector the hunt for underexposed and undervalued companies is fast on. One such company is Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF); Theralase designs, develops, manufactures and markets, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. With a strong pipeline of developments leading to a Phase I clinical trial in 2015 the company looks to have a promising 2014.
Theralase Releases 3Q2013 Financial Results
ACCESSWIRE - Fri Nov 29, 6:02AM CST
Toronto, Ontario - November, 29, 2013 Theralase Technologies Inc. (TSXV: TLT) released its third quarter 2013 financial results today, demonstrating an increase in profitability by 40% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.
Theralase Completes Oversubscribed $3.15 M Equity Financing
ACCESSWIRE - Thu Nov 07, 6:26AM CST
Toronto, Ontario -//Accesswire// November 7, 2013 Theralase Technologies Inc. (TSX-V: TLT) announced today that it has completed an oversubscribed equity financing raising CAN $3,150,000 via private placement offering. ("Private Placement"
Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
IIROC Trade Resumption - Theralase Technologies Inc.
Newsfile Corp - Thu Aug 29, 7:18AM CDT
Trading resumes in:
IIROC Trade Halt - Theralase Technologies Inc.
Newsfile Corp - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC:
IIROC: Halt, Theralase Technologies Inc.
Marketwire Canada - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants:
Theralase Releases Financial Results for First Quarter 2013
ACCESSWIRE - Thu May 30, 3:10PM CDT
Toronto, Ontario - May 30, 2013, Theralase Technologies Inc. (TSXV: TLT) released its first quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies .
Theralase Launches New Head Office and Therapeutic Laser Centre
ACCESSWIRE - Tue May 28, 6:00AM CDT
TH
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference
ACCESSWIRE-TNW - Thu May 16, 6:00AM CDT
Toronto, Ontario - May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) ("Theralase" announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.
Theralase Announces 2012 Year End Financials; Theralase Advances Therapeutic Laser and Cancer Destruction Technologies
ACCESSWIRE-TNW - Wed May 01, 3:00PM CDT
Toronto, Ontario - May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.
Theralase Applies to TSX Venture Exchange for Warrant Extension
ACCESSWIRE-TNW - Thu Mar 28, 3:10PM CDT
Toronto, ON - March 28, 2013 - Theralase Technologies Inc. (TSXV: TLT) ("Theralase" announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants.
Theralase Releases 2013 Financials
ACCESSWIRE - Wed Apr 30, 3:31PM CDT
Toronto, ON / ACCESSWIRE / April 30, 2014 / Theralase Technologies Inc. (herein "Theralase"
(TSXV: TLT) (TLTFF: OTCBB) released its 2013 financial results today, demonstrating an increase in profitability by 24% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies. Theralase Could Light Up Cancer Therapeutics
ACCESSWIRE - Thu Apr 24, 9:27AM CDT
Whitefish, MT / April 24, 2014 / Cancer patients don't have many good treatment options. Once the disease is detected, most oncologists will surgically remove as much as possible and then use powerful radiation and chemotherapy to kill as many cells in those areas as possible. The side effects from these treatments can be terrible and patients are at a higher risk of additional complications given the weakened state of the immune system.
Theralase Anti-Cancer Technology Validated at International Conference
ACCESSWIRE - Thu Apr 24, 6:15AM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 24, 2014 / Theralase Technologies Inc. ("Theralase'
(TSXV: TLT) (TLTFF: OTCBB) announced today new research on its Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, has been peer reviewed and approved for presentation at the 16th Annual Laser Optics International Conference to be held in June 2014. Theralase Research Accepted at International Conference
ACCESSWIRE - Tue Apr 22, 6:05AM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 22, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that its Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, has been peer reviewed and approved for presentation at the renowned International Conference on Laser Applications in Life Sciences to take place in Ulm, Germany in June 2014.
Theralase Advances Sales and Marketing
ACCESSWIRE - Tue Apr 15, 6:22AM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 15, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that it is advancing on its sales and marketing mandate through the hiring of Mr. Derek Small as Director of Sales and Marketing.
Theralase Developing Next Generation Medical Lasers
ACCESSWIRE - Tue Mar 25, 6:13AM CDT
Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the expansion of its engineering team to develop and commercialize its next generation of smart medical laser technologies. This highly trained engineering team will be instrumental in developing Theralase products to eliminate pain and heal tissue, a $100 Billion industry in the US and to destroy cancer, a $77 Billion industry in the US.
Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Mar 12, 6:05AM CDT
Theralase Technologies Inc. (OTCBB: TLTFF) (TSX VENTURE: TLT) sells patented, superpulsed laser technology to healthcare practitioners to heal damaged tissue and eliminate pain. Theralase is also developing the next generation cancer treatment combining patented light activated compounds with laser technology to hunt down and destroy cancer.
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra...
ACCESSWIRE - Thu Feb 13, 6:01AM CST
Toronto, Ontario - February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25).
Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
ACCESSWIRE - Wed Feb 12, 9:20AM CST
2013 was a great year for Life Sciences stocks and the momentum created last year is being carried into 2014 - with a flurry of successful IPOs and financings. According to organizers at the JP Morgan Health Care Conference in January attendance was much higher than what they had anticipated and bankers were eager to do deals as more dollars flow into the space. As the wider market draws its attention to the sector the hunt for underexposed and undervalued companies is fast on. One such company is Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF); Theralase designs, develops, manufactures and markets, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. With a strong pipeline of developments leading to a Phase I clinical trial in 2015 the company looks to have a promising 2014.
Theralase Releases 3Q2013 Financial Results
ACCESSWIRE - Fri Nov 29, 6:02AM CST
Toronto, Ontario - November, 29, 2013 Theralase Technologies Inc. (TSXV: TLT) released its third quarter 2013 financial results today, demonstrating an increase in profitability by 40% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.
Theralase Completes Oversubscribed $3.15 M Equity Financing
ACCESSWIRE - Thu Nov 07, 6:26AM CST
Toronto, Ontario -//Accesswire// November 7, 2013 Theralase Technologies Inc. (TSX-V: TLT) announced today that it has completed an oversubscribed equity financing raising CAN $3,150,000 via private placement offering. ("Private Placement"
Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
IIROC Trade Resumption - Theralase Technologies Inc.
Newsfile Corp - Thu Aug 29, 7:18AM CDT
Trading resumes in:
IIROC Trade Halt - Theralase Technologies Inc.
Newsfile Corp - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC:
IIROC: Halt, Theralase Technologies Inc.
Marketwire Canada - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants:
Theralase Releases Financial Results for First Quarter 2013
ACCESSWIRE - Thu May 30, 3:10PM CDT
Toronto, Ontario - May 30, 2013, Theralase Technologies Inc. (TSXV: TLT) released its first quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies .
Theralase Launches New Head Office and Therapeutic Laser Centre
ACCESSWIRE - Tue May 28, 6:00AM CDT
TH
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference
ACCESSWIRE-TNW - Thu May 16, 6:00AM CDT
Toronto, Ontario - May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) ("Theralase"
announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source. Theralase Announces 2012 Year End Financials; Theralase Advances Therapeutic Laser and Cancer Destruction Technologies
ACCESSWIRE-TNW - Wed May 01, 3:00PM CDT
Toronto, Ontario - May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.
Theralase Applies to TSX Venture Exchange for Warrant Extension
ACCESSWIRE-TNW - Thu Mar 28, 3:10PM CDT
Toronto, ON - March 28, 2013 - Theralase Technologies Inc. (TSXV: TLT) ("Theralase"
announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants. 
